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Gene expression alterations 
in salivary gland epithelia 
of Sjögren’s syndrome patients 
are associated with clinical 
and histopathological 
manifestations
Ariana Dela Cruz1,7, Vinay Kartha2,7, Andrew Tilston‑Lunel3,7, Rongjuan Mi1,3, 
Taylor L. Reynolds4, Michael Mingueneau4, Stefano Monti2, Janicke L. Jensen5, 
Kathrine Skarstein6, Xaralabos Varelas3* & Maria A. Kukuruzinska1*
Sjögren’s syndrome (SS) is a complex autoimmune disease associated with lymphocytic infiltration 
and secretory dysfunction of salivary and lacrimal glands. Although the etiology of SS remains unclear, 
evidence suggests that epithelial damage of the glands elicits immune and fibrotic responses in SS. To 
define molecular changes underlying epithelial tissue damage in SS, we laser capture microdissected 
(LCM) labial salivary gland epithelia from 8 SS and 8 non‑SS controls for analysis by RNA sequencing 
(RNAseq). Computational interrogation of gene expression signatures revealed that, in addition to a 
division of SS and non‑SS samples, there was a potential intermediate state overlapping clustering of 
SS and non‑SS samples. Differential expression analysis uncovered signaling events likely associated 
with distinct SS pathogenesis. Notable signals included the enrichment of IFN‑γ and JAK/STAT‑
regulated genes, and the induction of genes encoding secreted factors, such as LTF, BMP3, and 
MMP7, implicated in immune responses, matrix remodeling and tissue destruction. Identification of 
gene expression signatures of salivary epithelia associated with mixed clinical and histopathological 
characteristics suggests that SS pathology may be defined by distinct molecular subtypes. We 
conclude that gene expression changes arising in the damaged salivary epithelia may offer novel 
insights into the signals contributing to SS development and progression.
Sjögren’s syndrome (SS) is a debilitating complex autoimmune disease presenting as exocrinopathy of salivary 
and lacrimal glands with frequent systemic extraglandular manifestations and an increased risk of non-Hodgkin’s 
 lymphoma1–6. Damage to salivary and lacrimal glands from SS impairs their ability to produce saliva and tears, 
resulting in xerostomia and xerophthalmia. SS is a multifactorial disease that comprises various combinations of 
dry eyes, dry mouth, reduced tear and saliva secretion, presence of autoantibodies, focal lymphocytic infiltration 
of salivary glands, fatigue, vasculitis, joint and muscle pain, as well as peripheral nervous system  dysfunction4,7. 
Although to date, the origin of SS remains unknown, the prevailing model for SS has been that loss of secretory 
function is secondary to lymphocytic infiltrates.
Since defects in the immune system have long been considered to be the cause of SS, the majority of studies 
and therapeutic approaches have focused on aberrant immune  responses8–10. Analysis of genomic and epi-
genomic changes in SS has provided new insight into the understanding of disease  pathogenesis9,11–13. Gene 
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expression microarray studies on labial salivary glands and peripheral blood detected dysregulation of type 1 
interferon (IFN)-inducible  genes14. Additional upregulated genes involved in antigen presentation, lymphocyte 
development and activation, as well as interferon-induced chemokines were also identified. Interestingly, IFN-
γ-inducible genes, such as Signal transducer and activator of transcription (STAT) family members STAT1 
and STAT3, were also shown to be highly expressed in primary SS (pSS)15. Furthermore, IFN-mediated innate 
immune mechanisms have been implicated in the pathogenesis of pSS, where specifically 23 genes known to 
play a role in IFN signaling were  identified16. Two GWAS studies have been performed in pSS and among the 
SS-associated non-HLA genes they identified STAT4 and IRF5 encoding transcription factors, BLK coding for 
B cell kinase as well as genes encoding the IL-12A cytokine. Genes involved in NF-κB signaling and CXCR5 
chemokine production were also shown to be  upregulated9,17. Collectively, these studies provided a strong support 
for the role of innate immunity, as well as adaptive immune mechanisms, in the pathogenesis of pSS. Despite 
these advances, treatment strategies for SS disease are almost inexistent, and molecular mechanisms that drive 
disease onset are poorly understood.
One consistent feature of human autoimmunity is the finding that there is an initial phase in which patients 
have many of the serological abnormalities of autoimmune disease before they develop clinical  pathology18. In 
this respect, the immunobiology of the glandular epithelial cells within the target tissue likely plays a critical role 
in initiating events in SS. Indeed, accumulating evidence suggests that impaired glandular secretion develops 
independent of lymphocytic infiltration, and defective secretion precedes the immune response during SS onset, 
suggesting a role for the epithelium in the etiology of  SS2. For example, aberrantly high expression of BMP growth 
factors, such as BMP6, has been implicated in the induction of salivary and lacrimal gland dysfunction independ-
ent of the autoantibodies and immune infiltration associated with  SS19. Recent studies, including our own, have 
also shown that the structural integrity of the epithelium of SS patients is lost, and that these defects are associated 
with aberrant apical-basal  polarity20–25. Aberrant polarity can arise in various ways, including environmental 
toxins, viral infection, physical damage, and unbalanced hormone levels, and therefore it may be an early event 
that triggers disease states, including SS. Since structural changes of the epithelium of salivary glands may drive 
inflammation, the aim of this study was to elucidate molecular details of how epithelial structural dysfunction 
contributes to SS. We used laser capture microdissection of glandular epithelial regions (acini and ducts) from 
resected labial salivary glands of patients fulfilling or not fulfilling SS criteria (8 SS and 8 non-SS controls) and 
processed them for global transcriptomes using bulk RNAseq analysis. Our studies provide evidence that dam-
age to salivary gland epithelia is associated with changes in gene expression signatures that provide insights into 
deregulated pathways and cellular processes which may underlie predisposition to, and early onset of, SS. Col-
lectively, these findings provide support for the theory that alterations in gene expression arising in the salivary 
epithelia contribute to the etiology of SS. We postulate that the molecular sub-groups reflect varying stages of 
disease predisposition and that they may offer novel insights into the signals contributing to the progression of SS.
Results
Clinical characteristics of patients. Sixteen samples of labial salivary glands were obtained from female 
patients who presented with sicca symptoms to the Department of Otolayngology/Head and Neck Surgery at 
Haukeland University Hospital, Bergen. Patients were assessed for primary Sjögren’s Syndrome (pSS) based on 
the American-European Classification  Criteria26, where diagnosis of pSS required focal lymphocytic sialadenitis 
score (FS) of ≥ 1 or presence of anti-SSA/Ro or anti-SSB/La autoantibodies, as well as ocular symptoms of dry 
eyes, oral symptoms of dry mouth, positive Schirmer’s test, and reduced unstimulated salivary flow ≤ 1.5 mL in 
15 min (at least four positive tests including symptoms, or three objective tests). We categorized samples into 
two clinically distinct groups, patients diagnosed with SS (named SS, n = 8) or without SS (named non-SS, n = 8). 
Clinical characteristics of patients are shown in Table 1. The patient mean age was 53 ± 12.4 years, with three 
patients in the SS group presenting with anti-SSA/Ro and ANA antibodies, of which also two were positive for 
anti-SSB/La antibodies. All patients reported dry eyes and the majority reported dry mouth. Three SS patients 
had FS of 1, three had a FS of 2, with one patient presenting with FS of 3 and one with FS of 4. Interestingly, FS 
of either 1 or 4 were associated with positivity for all anti-SSA/Ro, anti-SSB/La and ANA, suggesting that these 
may be independent variables in our sample group. Likewise, there was no association between germinal centers 
(GCs) and autoantibody positivity. Furthermore, two of the non-SS patients had a negligible salivary flow rate, 
and there was little correlation between salivary flow rate and auto-antibody positivity in SS patients.
Histopathological evaluation of H&E sections of biopsies from non-SS and SS patients revealed that SS sam-
ples were characterized by acinar atrophy, ductal dilation, detectable fat infiltration, and lymphocytic aggregates 
with FS ≥ 1, whereas non-SS tissues were generally normal in appearance with some acinar atrophy, ductal dila-
tion, and scattered inflammation (Fig. 1). From analysis of clinical presentation, we observed that there was no 
correlation between SS and non-SS groups for the parameters of positive Schirmer’s test, saliva secretion, dry 
mouth or dry eyes. However, the presence of anti-SSA/Ro, anti-SSB/La, ANA autoantibodies, FS ≥ 1, and the 
presence of CD21+ GCs were only observed in the SS group. When assessed for age, the SS group was significantly 
older than the non-SS group (60.2 ± 10.7 years vs 45.6 ± 9.6 years respectively; p = 0.012).
Subclustering of epithelial‑derived RNA‑seq data reveals potential SS subgroups. To gain 
insight into the molecular characteristics of two groups with sicca symptoms, eight non-SS and eight SS, all sam-
ples were subjected to laser capture microdissection (LCM) of epithelial regions followed by RNAseq analysis to 
identify biomarkers restricted to the epithelial compartment of the labial salivary glands. We evaluated the entire 
set by principal component analysis (PCA) selected by the expression level of all differentially expressed (DE) 
genes. It was evident that the SS and non-SS samples did not entirely cluster together and rather three distinct 
transcriptomic subclusters were observed: a group containing non-SS samples (named Group A, n = 3), a group 
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containing SS (named Group B, n = 3), and a group containing samples from both groups (named Group AB, 
n = 10) (Fig. 2a,b). The position of these groupings demonstrates different features of RNA expression in the epi-
thelial tissues, suggesting that transcriptomic profiling of patient samples may characterize important molecular 
events in SS pathogenesis compared to grouping by clinical characteristics alone.
When assessed for age, Group B (69.3 ± 12.7 years) was significantly older than both the Group AB (52.2 ± 7.4 
years; p = 0.020) and Group A (39.0 ± 6.6 years respectively; p = 0.002), whereas there was no significant age dif-
ference between Group A and Group AB. Clinical findings for the RNA-Seq groupings revealed that all samples 
in Group B had GCs with FS of ≥ 2. One of the patients in this group developed lymphoma during the course of 
this study. In the mixed Group AB, two of the five SS patients also had GCs and lower mean FS. There was no cor-
relation observed for RNAseq grouping for the presence of anti-SSA/Ro, anti-SSB/La and ANA autoantibodies, 
salivary flow and Schirmer test. Likewise, no specific pattern regarding Group A patients was detected, except 
that all presented with positive Schirmer tests and a subjective feeling of dry eyes.
Differential expression testing of SS subgroups. Genome-wide differential expression testing was 
performed using DESeq2 for multiple group comparisons. First, we tested the clinical grouping of SS against 
non-SS. Second, we compared the RNAseq grouping of Group B against Group A samples to determine if there 
were differences in gene expression between clinical diagnosis of Sjögren’s and principal component analysis 
(PCA) for clustering. Third, the RNAseq Group A and Group B groups were compared to the Group AB.
RNAseq analysis of the epithelial regions for the groupings clinically diagnosed with SS showed no sig-
nificantly altered differentially expressed (DE) genes compared to the non-SS group out of 25,444 total genes 
analyzed (Fig. 2c). However, when analyzed according to PCA clustering, there were 1247 DE genes between 
Group B and Group A at a FDR cut-off of 0.05 (Fig. 2c), further demonstrating a benefit of clustering the samples 
according to RNAseq data. Table 2 summarizes the top 10 DE upregulated and downregulated genes for both 
clinical Sjögren’s (SS vs non-SS) and RNAseq (Group B vs Group A vs Group AB) groupings.
Inter-group analysis with the Group AB subcluster revealed the following comparisons: 767 DE genes com-
pared to the Group A (FDR cut-off = 0.05) and 1480 DE genes compared to Group B (FDR cut-off = 0.05). While 
strictly not statistically meaningful, the FDR-value ranking was used to define signatures to be annotated by 
pathway enrichment analysis.
Pathway analysis identifies epithelial signals associated with SS. Gene set enrichment analysis 
(GSEA) was conducted for each of the groups, and hallmark gene sets were evaluated (Fig. 3a). Comparison of 
SS vs non-SS groupings revealed 8 signaling pathways that were statistically upregulated and 27 pathways down-
regulated in the SS group (Supplementary Table S1). Notably, immunological and autoimmune disease pathways 
were enriched in the SS group while cholesterol and protein-related metabolic pathways were downregulated 
(Fig. 3b,c). Interferon response genes were upregulated in both the clinical SS and RNAseq (Group B) groupings 
compared to non-SS and Group A samples, respectively, suggesting conservation of relevant processes reflected 
in RNA profiling. Further hallmark GSEA of comparisons between the subcluster groupings revealed 9 upregu-
Table 1.  Clinical characteristics of patients whose salivary gland biopsies were analyzed by RNAseq. ANA 
antinuclear antibodies; Saliva secretion (unstimulated flow); normal flow > 1.5 ml/15 min; Schirmer test 
positive when reduced tear secretion (objective test); Dry mouth and dry eyes, subjective symptoms from the 
patient, FS Focus Score, NT not determined. Germinal center-like structures may result from the deregulated 
proliferation and infiltration of lymphocytes in glandular tissue.
Clinical 
classification Patient Age Gender Anti-SSA/Ro Anti-SSB/La ANA Schirmer test
Saliva secretion 




Non-SS1 45 F − − − + 0.5 + + − −
Non-SS2 53 F − − − − 0.0 + + − −
Non-SS3 51 F − − − − 0.0 + + − −
Non-SS4 51 F − − − + 3.2 + + − −
Non-SS5 34 F − − − + 1.0 + + − −
Non-SS6 59 F − − − + 2.6 + + − −
Non-SS7 32 F − − − + 4.0 − + − −
Non-SS8 40 F − − − + 2.1 + + − −
SS
SS1 62 F + + + − 1.7 + + 1 −
SS2 74 F − − − + 0.9 + + 2 +
SS3 51 F − − − + 1.7 + + 1 −
SS4 56 F − − − + 2.8 + + 1 −
SS5 53 F − − − + 1.8 + + 2 +
SS6 79 F + + + NT 1.0 + + 4 +
SS7 55 F − − − + 4.4 + + 2 +
SS8 52 F + − + + 6.6 − + 3 +
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lated and 23 downregulated pathways for Group B vs Group A, 21 upregulated and 13 downregulated pathways 
for Group B vs Group AB, and 30 upregulated and 1 downregulated pathway for Group A vs Group AB (Fig. 3a).
Compared to Group AB, both Group A and Group B showed upregulated pathways in genes encoding com-
ponents of the apical junction complex and apical surface of epithelial cells, epithelial–mesenchymal transition 
and coagulation, all indicative of changes in epithelial cell polarity. Significantly, the Group AB showed inter-
mediary expression of genes involved in protein secretion and those activated through the mTORC1 complex 
as enrichment of genes in these pathways was low in Group B and high in Group A.
While the RNAseq data generated from the epithelia of non-SS and SS salivary glands showed complexity in 
gene signatures among patient samples, a closer comparison revealed genes that encode secreted proteins that 
may contribute to the disease. These included genes encoding lactotransferrin (LTF), matrix metalloproteinase 7 
(MMP7), bone morphogenetic protein 3 (BMP3), interferon-inducible proteoglycan testican-2 (SPOCK2) as well 
as cytokines IL-15, IL-19 and BAFF (TNFSF13B). Both BAFF and IL-15 have been shown to be associated with 
B cell development, physiology and  malignancy13,27. Furthermore, SPOCK2 was also identified as a downstream 
target of lncRNA-dependent miRNAs involved in the modulation of ECM genes in  SS13.
RNAscope analysis reveals increased LTF, MMP7, and BMP3 expression in Sjögren’s labial sali‑
vary gland epithelia. Among the top genes whose transcriptional expression was increased in the RNAseq 
analysis of the SS grouping were LTF and in Group B were MMP7 and BMP3. LTF is a glycoprotein found in 
exocrine fluids, such as milk, saliva, tears, and nasal secretions, as well as in secondary granules of polymor-
phonuclear leukocytes (PMNs) and was previously shown to be upregulated on the protein level in saliva of SS 
 patients28,29. MMP7 belongs to a family of ubiquitous proteolytic enzymes, the MMPs, and has been shown to be 
Figure 1.  Minor salivary glands biopsies. H&E staining of minor salivary gland biopsies from: (a) Non-SS 
control showing normal appearing salivary gland tissue with few lymphocytic cells, (b) Non-SS control with 
scattered lymphocytes and some interstitial fibrosis, (c) SS patient with FS = 1 showing a focal lymphocytic 
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elevated in corneal specimens of pSS  patients30. BMP3 is a member of the TGF-β superfamily of proteins, associ-
ated with inflammation in rheumatoid arthritis patients with concomitant inhibition of bone  repair31.
In order to validate the increased LTF, MMP7, and BMP3 expression identified in our RNAseq data, we 
performed independent RNAscope analyses for expression of these genes. This in situ hybridization approach 
is based on the amplification of target-specific signals but not non-specific background hybridization. Samples 
were counterstained with pan-cytokeratin in order to restrict analysis of RNA to epithelial regions and analyzed 
using the CellProfiler image analysis  software32–34 (http:// www. cellp rofil er. org). To increase our sample size, we 
included an additional group of labial salivary gland samples obtained from the University of Oslo. Figure 4 
illustrates combined RNAscope analysis of LTF, MMP7 and BMP3 expression from the Bergen samples described 
in Table 1 and Oslo samples described in Table 3. We note that the age of SS patients in the Oslo cohort was not 
significantly different than the non-SS group (51.0 ± 19.1 years vs 44.5 ± 13.1 years respectively) although the new 
Oslo cohort included SS samples from two male patients and the SS groups were mostly positive for autoantibod-
ies (Table 3). Quantitation of the RNA showed significant increases in the epithelial percentage of LTF, MMP3, 
and BMP3 expression in the SS group compared to the non-SS group (Fig. 4a,b). The observed increases in LTF, 
MMP3 and BMP3 were not driven by age as there was no significant correlation between patient age and expres-
sion of either gene (Fig. 4, “Methods”, “Statistical analysis”). These results correlate with our RNAseq findings of 
increased epithelial expression of LTF, MMP7, and BMP3 in SS. 
Discussion
Sjögren’s syndrome (SS) is a debilitating autoimmune disease with poorly understood etiology and limited bio-
markers available for early detection and prognosis. In this study, we generated and annotated gene expression 
signatures of labial salivary gland epithelia from human SS and non-SS patients using RNAseq and computational 
analyses with a goal of obtaining new insights into molecular changes associated with this disease. Our studies 
Figure 2.  RNAseq of LCM isolated epithelia from 8 non-SS and 8 SS patients. (a) PCA of total gene expression 
data reveals segregation between non-SS (Group A) and SS (Group B) samples and similarities between non-SS 
and SS (Group AB), identifying a new sub-group with mixed clinical features but the same transcriptional 
profile. Groups were defined as: Group A (non-SS, n = 3), Group AB (mixed non-SS/SS, n = 10), and Group B 
(SS, n = 3). (b) Sample-sample distance heat map further clusters the sample set. (c) Comparison of outputs of 
the number differentially expressed (DE) genes at different filtered FDR cut-off levels. When the biopsies were 
analyzed for DE genes by RNAseq cluster, a greater number of DE genes were observed.
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provide evidence that damage to salivary gland epithelia is associated with changes in gene expression signatures 
that provide insights into deregulated pathways and cellular processes which may underlie predisposition to and 
early onset of SS. We postulate that the molecular sub-groups identified in our studies reflect varying stages of dis-
ease predisposition and that they may offer novel insights into the signals contributing to the development of SS.
PCA analysis showed a clear segregation of gene signatures between some non-SS and SS patients (Fig. 2). In 
addition, it revealed a novel subgroup of gene signatures derived from both non-SS and SS tissues that may reflect 
a mixed patient population. Interestingly, however, analyses of clinicopathological features of salivary epithelia 
from SS and non-SS patient cohorts did not reveal any consistent association with GCs and focus scores; indeed, 
there were no substantial differences among these patient groups in autoantibody positivity, saliva secretion, 
tear secretion, and subjective feeling of dry eyes or dry mouth. Our identification of a mixed gene expression 
Table 2.  Lists of differentially expressed genes based on RNAseq.
Gene symbol Description Fold change (log2) Adjusted p value
(a) List of top 10 genes upregulated in SS (n = 8) than non-SS (n = 8)
LTF Lactotransferrin 0.980 0.099
REC8 REC8 meiotic recombination protein 0.947 0.099
HCP5 HLA complex P5 (non-protein coding) 0.935 0.099
SMPX Small muscle protein, X-linked 0.908 NA
IL15 Interleukin 15 0.882 NA
CA13 Carbonic anhydrase XIII 0.816 0.099
SNORD116-6 Small nucleolar RNA, C/D box 116-6 0.806 0.272
APOL1 Apolipoprotein L, 1 0.802 0.197
HLA-F Major histocompatibility complex, class I, F 0.793 0.256
CD8A CD8a molecule 0.792 NA
(b) List of top 10 genes downregulated in SS (n = 8) than non-SS (n = 8)
CA8 Carbonic anhydrase VIII − 0.762 0.275
CABS1 Calcium-binding protein, spermatid-specific 1 − 0.757 0.275
FDPSP5 Farnesyl diphosphate synthase pseudogene 5 − 0.730 NA
SCD Stearoyl-CoA desaturase (delta-9-desaturase) − 0.729 0.275
SCDP1 Stearoyl-CoA desaturase (delta-9-desaturase) pseudogene 1 − 0.725 NA
LINC01207 Long intergenic non-protein coding RNA 1207 − 0.718 0.326
RSL24D1P1 Ribosomal L24 domain containing 1 pseudogene 1 − 0.716 NA
VSIG10L V-set and immunoglobulin domain containing 10 like − 0.669 0.348
SEMA3D Sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3D − 0.668 NA
UNC5A Unc-5 homolog A − 0.659 0.408
(c) List of top 10 genes after RNAseq subclustering that are upregulated in Group B (n = 3) than Group A (n = 3)
MMP7 Matrix metallopeptidase 7 2.522 7.36 ×  10–8
LINC00639 Long intergenic non-protein coding RNA 639 2.297 2.96 ×  10–6
KCNB1 Potassium channel, voltage gated Shab related subfamily B, member 1 2.274 3.30 ×  10–7
LINC00284 Long intergenic non-protein coding RNA 284 2.273 3.61 ×  10–6
CLU Clusterin 2.223 2.73 ×  10–9
RARRES1 Retinoic acid receptor responder (tazarotene induced) 1 2.125 2.70 ×  10–6
C19orf68 Chromosome 19 open reading frame 68 2.119 4.17 ×  10–6
SH3D21 SH3 domain containing 21 2.062 5.81 ×  10–6
BMP3 Bone morphogenetic protein 3 2.057 6.22 ×  10–6
SLC38A3 Solute carrier family 38, member 3 2.022 NA
(d) List of top 10 genes after RNAseq subclustering that are downregulated in Group B (n = 3) than Group A (n = 3)
CALML5 Calmodulin-like 5 − 2.407 4.46 ×  10–17
VSIG10L V-set and immunoglobulin domain containing 10 like − 2.375 9.37 ×  10–15
HPSE Heparanase − 2.152 1.52 ×  10–6
CABS1 Calcium-binding protein, spermatid-specific 1 − 2.081 7.43 ×  10–6
MUC7 Mucin 7, secreted − 2.008 7.88 ×  10–8
FGF12 Fibroblast growth factor 12 − 1.946 1.28 ×  10–7
TESC Tescalcin − 1.911 1.41 ×  10–6
DNASE2B Deoxyribonuclease II beta − 1.898 0.000155
SCD Stearoyl-CoA desaturase (delta-9-desaturase) − 1.863 3.99 ×  10–6
FADS2 Fatty acid desaturase 2 − 1.853 1.54 ×  10–5
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signature subgroup (Group AB) sheds novel insights into molecular changes in labial salivary glands that may 
reflect early disease in individuals whose symptoms do not meet the criteria for SS diagnosis.
Better understanding of the molecular features that underlie different subsets of patients is essential for 
disease diagnostics, prognosis, and effective treatment interventions. The focal infiltration of the salivary gland 
provides the basis for the focus score used to describe the pathological changes of the salivary glands in the cur-
rently used classification criteria for pSS. While the European-American Consensus Group  criteria26 include 
symptoms of dry mouth and dry eyes, the ACR-criteria include only objective criteria of reduced secretion of 
saliva and tears, ocular staining, positive focus score, and presence of anti-SSA/Ro in  serum35. Both classifica-
tion criteria for pSS require that the patients have anti-SSA/Ro antibodies and/or have a positive focus score, 
but do not include germinal centers. The epithelial gene expression profiles we describe show some association 
with clinical/pathological features of SS, but such molecular similarities are also evident in non-SS patients. This 
may be a consequence of the stochastic nature of clinical/pathological characteristics currently used to stratify 
patients into non-SS and SS groups.
Changes in SS epithelial and stromal tissue biology have been increasingly shown to play a role in SS 
 pathobiology13,36. Previous studies revealed alterations in subpopulations of epithelial cells in NOD/ShiLtJ mouse 
model of SS, revealing a decrease in the tissue area of secretory cells in favor of ductal epithelial cells and expan-
sion of keratin 5-positive basal  cells37. Additional studies highlighted the key roles of the innate and adaptive 
immune systems, as well as stromal cells, in promoting the pro-inflammatory  milieu38,39. A more recent report 
using an LCM approach coupled with RNAseq analyses described identification of cell-type and disease-specific 
markers in SS  patients40. However, the latter study did not strictly focus on salivary gland epithelia, and thus 
precluded identification of gene signatures associated only with the epithelial compartment. Additionally, recent 
analyses of PBMCs from SS patients provided evidence for the involvement of the perturbed long non-conding 
RNAs (lncRNAs)—microRNAs axes in the expression of genes involved in the pathogenesis of SS, including 
those with roles in B cell function and extracellular matrix remodeling, among  others13. Here, our results identi-
fying IL-15 and BAFF cytokines with important functions in B cell physiology, as well as SPOCK2 proteoglycan 
Figure 3.  Hallmark gene set analyses from the entire RNAseq dataset. (a) Heatmap of hallmark gene sets that 
are significantly up (red) or downregulated (blue) in the respective indicated pathology. (b) Gene set enrichment 
analysis (GSEA) of hallmark gene sets that are significantly enriched in SS (n = 8) vs non-SS (n = 8). (c) GSEA of 
hallmark gene sets that are significantly enriched in non-SS (n = 8) vs SS (n = 8). NES nominal enrichment score, 
FDR false discovery rate. A gene set shows significant enrichment at a FDR < 0.25.
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Figure 4.  RNAscope validation of gene expression changes identified from RNAseq of SS epithelial tissues. 
(a) SS vs non-SS biopsies were probed for lactotransferrin (LTF), bone morphogenetic protein 3 (BMP3), and 
matrix metalloproteinase 7 (MMP7) RNA (green) by in situ RNAscope and counterstained with pan-cytokeratin 
to mark epithelium (pCK, red). Scale bars = 20 µm. (b) LTF, BMP3, and MMP7 RNAs were quantified in the 
respective pCK-positive tissues from patients in the Bergen (green) and Oslo (red) cohorts, revealing increased 
epithelial expression of LTF, BMP3, and MMP7 in SS tissues. The average % LTF, BMP3, and MMP7 area 
per patient sample in epithelial regions is shown. Data points represent each patient from Bergen and Oslo 
cohorts per condition of non-SS or SS. Each data point denotes the average of a range of 2000–4000 epithelial 
cells scored across multiple tissue fields from each patient sample (***p < 0.001 compared to non-SS group 
determined with unpaired t tests).
Table 3.  Additional patient samples used for RNAScope (Oslo cohort). ANA antinuclear antibodies; Saliva 
secretion (unstimulated flow); Schirmer test positive when reduced tear secretion (objective test); Dry mouth 
and dry eyes, subjective symptoms from the patient, FS Focus Score.
Clinical 




Non-SSa 42 F − − − + − + + − −
Non-SSb 47 F − − − + − + + − −
Non-SSc 64 F − − − − + + + − −
Non-SSd 25 F − − − + − + + − −
Non-SSe 51 F − − − + + + + − −
Non-SSf 38 F − − − + − + + − −
SS
SSa 49 F + + + + + + + 1 −
SSb 30 M + + + + + + + 1 −
SSc 38 F − − − + + + + 2 +
SSd 79 M + + + + + − + 1 −
SSe 59 F + − + + + + + 1 −
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contributing to the increasingly recognized roles of the stromal compartment in the pathogenesis of  SS36, provide 
important new information into their epithelial origin in SS.
In addition to signals known to be enriched in SS, including IFN-γ and JAK/STAT-regulated genes, and genes 
encoding secreted factors implicated in immune responses, our studies identified LTF, also known as lactoferrin 
(LF), to be upregulated in expression in SS epithelia compared to non-SS tissues. Increased levels of salivary LTF 
with some relationship to the labial salivary gland histopathology grade were reported  previously28, while no sig-
nificant changes in LTF expression were detected in tear secretions in  SS41. LTF is an iron-binding multifunctional 
glycoprotein known to function in the prevention of infections, late onset sepsis, and necrotizing  enterocolitis29. 
LTF has been shown to stimulate a balanced T-helper-1/T-helper-2 cytokine immune response and to be a part 
of the innate defense, mainly at  mucosa42. In our study, the observed increase in LTF gene expression in SS ductal 
epithelia suggests that it may be a relevant biomarker predictive of early disease with a potential causal effect on 
the induction of immune response.
Our data also show that MMP7 and BMP3 transcripts are upregulated in labial salivary glands from SS 
patients. MMP7 is a member of ubiquitous MMPs with important functions in tissue remodeling during devel-
opment, but whose inappropriate expression has been linked to tissue destruction in autoimmune rheumatoid 
 arthritis43 and with corneal melting in patients with primary  SS30. This suggests that upregulation of MMP7 in 
labial tissues from SS patients is likely to contribute to salivary gland destruction. In contrast, relatively less is 
known about the role of BMP3 in pSS. Previous studies documented increased expression of BMP6 in salivary 
and lacrimal glands from human SS patients independent of  autoantibodies19. To date, increased expression of 
BMP3 has been linked to immune infiltration in rheumatoid arthritis and inhibition of bone  repair31. Thus, our 
RNAseq-based identification of BMP3 in salivary epithelia from SS patients may provide additional mechanistic 
insights into how inflammation induces BMP3 expression to drive epithelial dysfunction in pSS.
Accumulating evidence suggests a role for the epithelium in the etiology of SS. Impaired epithelial secretion 
has been reported to develop independently of lymphocytic infiltration and frequently, defective secretion pre-
cedes the immune response during SS  onset2. Epithelial defects are often accompanied by pro-fibrotic changes 
in the stroma indicating remodeling of the extracellular matrix and fibroblast  activation36. Here, our findings 
align alterations in gene expression signatures in the salivary epithelia with different degrees of compromised 
salivary and lacrimal glands’ function. Collectively, these studies offer a molecular explanation for exocrine tissue 
dysfunction as it progresses to SS and suggest that transcriptional signatures may serve as predictive biomarkers 
for early and advanced disease.
Methods
Patient selection and sample collection. The study protocol was approved by the Norwegian Regional 
Committee for Medical and Health Research Ethics of West (REK 2009/686) and South-East Norway (REK 
2010/1292-1). The study was performed in compliance with the tenets of the Declaration of Helsinki. Prior 
to participation in the study, written informed consent was obtained from all participants. The data was de-
identifed prior to analysis.
Labial salivary glands were obtained from a total of 27 patients with sicca symptoms. Based on the Ameri-
can-European Consensus  Criteria26, these patients were sub-divided into 13 pSS (focus score (FS) 1–4) and 14 
non-SS sicca controls (FS < 1). Inclusion criteria were: SS-patients fulfilling the AECG classification for pSS; 
non-SS controls were patients evaluated for SS, but not fulfilling the AECG classification. Importantly, none 
of the non-SS controls had a positive focus score or positive anti-SSA/Ro or anti-SSB/La autoantibodies. All 
participants provided informed consent prior to the initiation of this study. Clinical characteristics of patients 
whose minor salivary gland (SG) biopsies were analyzed for RNAseq are summarized in Table 1 (Bergen cohort) 
and for RNAscope analyses in Table 3 (Oslo cohort). These included assessment of objective tests of antinuclear 
antibodies (ANA, anti-SSA/Ro, anti-SSB/La), saliva secretion (unstimulated flow of whole saliva), tear secre-
tion by Schirmer test, FS, and germinal center (GC)-like structures, as well as subjective symptoms noted by the 
patients (dry mouth and dry eyes).
Histopathology. Paraffin-embedded, formalin-fixed human salivary gland tissue sections, 5-µm-thick, 
were stained with hematoxylin and eosin (H&E) and focal lymphocytic infiltration areas in H&E slides were cap-
tured and assessed using Aperio digital technology (Leica Biosystem). Minor SG FS of SS patients was assessed 
based on the currently accepted  criteria4. The sections were evaluated by one oral pathologist (KS) in order to 
determine their FS. The tissue sections were further assessed for the presence of GC-like structures both on H&E 
sections and with an additional staining with CD21 (a marker of follicular dendritic cells) to improve the reli-
ability of GC  identification44. Fresh frozen biopsies from the Bergen cohort characterized in Table 1, were used 
for RNAseq analyses. Additional minor SG biopsies from another patient cohort (Oslo cohort, Table 3) were 
used for immunofluorescence labeling and RNAscope analyses.
Laser capture microdissection (LCM) analysis. Fresh surgical specimens were preserved in the Tissue-
TEK OCT compound and frozen in isopentane, followed by storage at − 80 °C. Tissue sections (5-μm-thick) 
were stained with an ethanol-based cresyl violet and eosin stain, followed by examination under the microscope 
and annotation of epithelium and inflammatory infiltrates on digital images. Acinar and ductal epithelium was 
subsequently captured by LCM using a Leica LMD6 microdissection system with regions containing inflamma-
tory cells being excluded.
RNAseq analyses. RNA extraction and RNA sequencing. RNA was isolated from laser capture microdis-
sected labial SG epithelia. Approximately 30–100 ng of RNA was isolated from each patient sample in 4 μl with 
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concentration of 7.5–25 ng/μl. Libraries for RNAseq were prepared using the Clontech Mammalian SMARTer 
Stranded Total RNASeq Kit Pico Input and then sequenced on an Illumina HiSeq 2500 instrument.
Processing RNA‑sequencing data. Paired-end RNA-sequencing reads for each sample were first trimmed for 
Illumina TruSeq adapters (AGA TCG GAA GAG CAC ACG TCT GAA CT CCA GTC AC and AGA TCG GAA GAG 
CGT CGT GTA GGG AAA GAG TGT AGA TCG GAA GA GCG TCG TGT AGG GAA AGA GTG TAG ATC TCG GTG 
GTC GCC GTA TCATT) using Cutadapt  tool45, setting the minimum read quality threshold to 20 for the start 
and end of the reads, and 15 for the minimum read length. Reads were then aligned to a reference hg19 genome 
using  Tophat246, with the number of allowed read mismatches, gap length and edit distance set to 1. Reads were 
then mapped to gene features using Ensembl hg19 (human genome release 19) genome annotations, and quanti-
fied as raw counts per feature using  featureCount47 using default parameters.
RNA differential expression testing. Gene feature raw RNA expression counts were normalized and tested for 
differential expression between different sample groupings using  DESeq248. In our analyses, we did not include 
age as a variable to be adjusted for when performing differential expression testing, although we are aware that 
age can be a confounding factor. Pairwise comparisons for the non-SS and SS RNAseq data provided sufficient 
coverage to estimate the differential expression of moderately to highly expressed genes.
Gene set enrichment analysis. For testing enrichment of pathways, genes were first ranked (genome-wide) 
based on their signed average log-fold change between group comparisons (e.g. Sjogren’s vs control), using the 
pre-ranked GSEA tool v2.1.1 given a specific differential expression ranked list (based on the ‘t-statistic’ of dif-
ferential expression). Data were then tested for enrichment of annotated hallmark gene sets from the molecular 
signature database (MSigDB)49 using the pre-ranked Gene Set Enrichment Analysis (GSEA)  tool50. Pathway-
based enrichment testing allowed the identification of coordinated sets of genes, and GSEA computationally 
determined if a defined set of genes was of statistical significance. We note that we did not use any fold-change 
cut-off here in addition to an FDR threshold.
RNAscope analyses. Formalin-fixed, paraffin-embedded non-SS and SS patient minor SG biopsies from 
the Bergen and Oslo patient cohorts were cut into 4-μm-thick sections and mounted onto Superfrost Plus slides. 
Samples were deparafinized and in situ hybridization was conducted using the RNAscope 2.5 HD Assay Reagent 
Kit (ACDBio), probing for lactotransferrin Hs-LTF (LTF) RNA, matrix metalloproteinase 7 Hs-MMP7 (MMP7) 
RNA, and bone morphogenetic protein 3 (BMP3) RNA, Positive Control Probe Hs-PPIB, and Negative Con-
trol probe Dap-B according to the manufacturer’s instructions (ACDBio). After the final amplification, fast-red 
chromogenic detection was performed. The epithelial localizations of LTF, MMP7, and BMP3 were determined 
by counterstaining the tissue sections with pan-cytokeratin protein. Sections were blocked with 5% donkey 
serum-TBST (DS-TBST) and incubated in primary antibody 1:100 in 5% DS-TBST for 60 min, followed by incu-
bation in 1:500 secondary goat anti-mouse conjugated with Alexa 647, counterstained with DAPI, and mounted 
in ProLong Gold Antifade and coverslipped. Image processing of the LTF/BMP3/MMP7 and pan-cytokeratin 
(pCK) signals was carried out on the free, open-source software CellProlifer v4.0.6 across all 2048X2048px 
 images32–34 (http:// www. cellp rofil er. org). We utilized the ability to mask nuclei and epithelial cells, followed by 
merging the two masks to define a full epithelial cell. Nuclei outside the epithelial mask was discarded from 
further analysis. Following the estimation of epithelial cells, we measured the area of pixels of RNAscope probes 
within the of area covered by the epithelial mask to derive the percentage of area covered by a probe signal over 
all the epithelial areas (Supplementary Figure 1). This analysis was carried out on all patients on a minimum of 
3 images per patient.
Statistical analysis. All analyses were performed with GraphPad Prism statistical software version 8.4.3 
(GraphPad Software Inc., La Jolla, CA, USA). Unpaired t tests were performed to compare values among groups 
for RNAscope of LTF, BMP3, and MMP7 expression. Each data point represents a patient. In order to determine 
the impact of age on gene expression, simple linear regression was calculated for each condition (Non-SS and 
SS), where age was the independent variable and expression of genes (LTF, BMP3, MMP7) quantified in the 
RNAscope experiment was the dependent variable. p < 0.05 considered to be statistically significant.
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